Antiphospholipid syndrome and systemic lupus erythematosus: Are they separate entities or just clinical presentations on the same scale?

Current Opinion in Rheumatology

Volumn 21, Issue 5, 2009, Pages 495-500

  Shoenfeld, Yehuda ^a,d   Meroni, Pier Luigi ^b   Toubi, Elias ^c  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY OF MILAN   (Italy)

^c BNAI ZION MEDICAL CENTER   (Israel)

^d SHEBA MEDICAL CENTER   (Israel)

Author keywords

Antinuclear antibodies; Complement; Lupus associated genes; Primary antiphospholipid syndrome; Systemic lupus erythematosus

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; COMPLEMENT COMPONENT C1Q; DOUBLE STRANDED DNA ANTIBODY; FC RECEPTOR IIA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MANNOSE BINDING LECTIN; NUCLEOSOME ANTIBODY; RAB PROTEIN;

ANTIBODY RESPONSE; ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE HEMOLYTIC ANEMIA; CENTRAL NERVOUS SYSTEM DISEASE; COMPLEMENT ACTIVATION; DNA POLYMORPHISM; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEREDITY; HUMAN; HYPOCOMPLEMENTEMIA; LIVEDO RETICULARIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; SKIN MANIFESTATION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA;

ANTIBODIES, ANTINUCLEAR; ANTIPHOSPHOLIPID SYNDROME; COMPLEMENT ACTIVATION; DIAGNOSIS, DIFFERENTIAL; GENETIC PREDISPOSITION TO DISEASE; HEMATOLOGIC DISEASES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM;

EID: 69549110747     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32832effdd     Document Type: Review

References (37)

1. Hughes GRV. The anticardiolipin syndrome. Clin Exp Rheumatol 1985; 3:285.
2. Asherson RA. A 'primary' antiphospholipid syndrome? J Rheumatol 1988; 15:1742-1746.
3. Mackworth-Young CG, Loizou S, Walport MJ. Primary antiphospholipid syndrome: features of patients with raised anticardiolipin antibodies and no other disorder. Ann Rheum Dis 1989; 48:362-367. (Pubitemid 19130194)
4. Miyakis S, Locksin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4:295-306.
5. Mackworth-Young C. Primary antiphospholipid syndrome: a distinct entry? Autoimmune Rev 2006; 5:70-75.
6. Krause I, Blank M, Fraser A, et al. The association of thrombocytopenia with systemic manifestations in antiphospholipid syndrome. Immunobiology 2005; 210:749-754. (Pubitemid 41683858)
7. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum 2002; 46:1019-1027. (Pubitemid 34303815)
8. Toubi E, Krause I, Fraser A, et al. Livedo reticularis is a marker for predicting multisystem thrombosis in antiphospholipid syndrome. Clin Exp Rheum 2005; 23:499-504. (Pubitemid 41447621)
9. Derksen RH, Gmelig-Meijling FH, deGroot PG. Primary antiphospholipid syndrome evolving in SLE. Lupus 1996; 5:77-80.
10. Rottem M, Krause I, Fraser A, et al. Autoimmune hemolytic anaemia in the antiphospholipid syndrome. Lupus 2006; 15:473-477. (Pubitemid 44147096)
11. Nochy D, Daugas E, Droz D, et al. The intrarenal vascular lesions associated with primary antiphospholipid syndrome. J Am Soc Nephrol 1999; 10:507-518. (Pubitemid 29117632)
12. Moroni G, Ventura D, Riva P, et al. Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis. Am J Kidney Dis 2004; 43:28-36. (Pubitemid 38049432)
13. Tektonidou MG, Sotsiou F, Nakopoulou L, et al. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations and long-term outcome. Arthritis Rheum 2004; 50:2569-2579. (Pubitemid 39062718)
14. Uthman I, Khamashta MA. Antiphospholipid syndrome and the kidneys. Semin Arthritis Rheum 2006; 35:360-367.
15. Jennekens FG, Kater L. The central nervous system in systemic lupus erythematosus. Pathogenetic mechanisms of clinical syndromes. Rheumatology (Oxford) 2002; 41:619-630.
16. Meroni PL, Tincani A, Sepp N, et al. Endothelium and the brain in CNS lupus. Lupus 2003; 12:919-928.
17. Roldan JF, Brey RL. Neurologic manifestations of the antiphospholipid syndrome. Curr Rheumatol Rep 2007; 9:109-115.
18. Gattorno M, Falcini F, Rawelli A, et al. Outcome of primary antiphospholipid syndrome in childhood. Lupus 2003; 12:449-453. (Pubitemid 36830118)
19. Tarr T, Lakos G, Bhattoa HP, et al. Primary antiphospholipid syndrome as the forerunner of systemic lupus erythematosus. Lupus 2007; 16:324-328. (Pubitemid 47074833)
20. Weber M, Hayem G, De Bandt M, et al. Classification of an intermediate group of patients with APS and lupus-like disease: primary or secondary APS? J Rheumatol 1999; 26:2131-2136.
21. Gomez-Puerta JA, Martin H, Amigo MC, et al. Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus? Medicine (Baltimore) 2005; 84:225-230.
22. Ames PR, Antinofi I, Ciampa A, et al. Primary antiphospholipid syndrome: a low-grade auto-inflammatory disease? Rheumatology 2008; 47:1832-1837. This study tests the inflammation and immune activation markers in thrombotic PAPS and identifies clinical and laboratory factors that are related to inflammation.
23. Tincani A, Franceschini F, Spunghi M, et al. Immunological abnormalities in the antiphospholipid syndrome. In Asherson RA, Cervera R, Piette JC, Shoenfeld Y, editors. The antiphospholipid syndrome II: autoimmue thrombosis. Elsevier; 2002. pp. 271-284.
24. Andreoli L, Pregnolato F, Burlingame RW, et al. Antinucleosome antibodies in primary antiphospholipid syndrome: a hint at systemic autoimmunity. J Autoimmun 2008; 30:51-57. In this study it is suggested that anti-NCS might be added to the mosaic of autoimmune phenomena characterizing PAPS patients and in particular those with more chance to evolve to SLE.
25. Cavazzana I, Nebuloni M, Cetin I, et al. Complement activation in antiphospholipid syndrome: a clue for an inflammatory syndrome. J Autoimmun 2007; 28:160-164. (Pubitemid 46680500)
26. Weiler H. Tracing the molecular pathogenesis of antiphospholipid syndrome. J Clin Invest 2008; 118:3276-3278. This is an elegant study that reports on the engagement of the complement receptor C5aR on neutrophils, that induces expression of the principal initiator of the blood-clotting mechanism, tissue factor, and blocking this downstream event of complement activation prevents antibody-induced fetal loss.
27. Shoenfeld Y, Blank M, Cervera R, et al. Infectious origin of the antiphospholipid syndrome. Ann Rheum Dis 2006; 65:2-6.
28. Ramos-Casals M, Campoamor MT, Chamorro A, et al. Hypocomplementemia in SLE and primary antiphospholipid syndrome: prevalence and clinical significance in 667 patients. Lupus 2004; 13:777-783. (Pubitemid 39457439)
29. Oku K, Atsumi T, Bohgaki M, et al. Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis. 2008. [Epub ahead of print] This special study shows hypocomplementemia to be frequent in patients with PAPS, reflecting complement activation and consumption, and found to be in correlation with anticoagulation activity.
30. Castro J, Balada E, Ordi-Ros J, Vilardell-Tarres M. The complex immunogenetic basis of systemic lupus erythematosus. Autoimmun Rev 2008; 7:345-351.
31. Sebastiani GD, Galeazzi M, Tincani A, et al. HLA-DPB1 alleles association of anticardiolipin and antibeta2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Lupus 2003; 12:560-563. (Pubitemid 36890151)
32. Karassa FB, Tricalinus TA, Ioannidis JP. Role of the Fcgamma receptor IIa polymorphism in susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis. Arthritis Rheum 2002; 46:1563-1571. (Pubitemid 34620203)
33. Sanghera DK, Manzi S, Bontempo F, et al. Role of an intronic polymorphism in the PDCD1 gene with the risk of sporadic systemic lupus erythematosus and the occurrence of antiphospholipid antibodies. Hum Genet 2004; 115:393-398. (Pubitemid 39341713)
34. Seelen MA, van der Bijl EA, Trouw LA, et al. A role for manose-binding lectin dysfunction in generation of autoantibodies in systemic lupus erythematosus. Rheumatology (Oxford) 2005; 44:111-119. (Pubitemid 40124343)
35. Fernandez DR, Telarico T, Bonilla E, et al. Activation of mammalian target of rapamycin controls the loss of TCR in lupus T cells through HRES-1/Rab4- regulated lysosomal degradation. J Immunol 2009; 182:2063-2073. In this study, the mTOR, which is a sensor of the mitochondrial transmembrane potential, is shown to be increased in lupus T cells, and that activation of mTOR interestingly causes the loss of TCR in lupus T cells through HRES-1/Rab4-dependent lysosomal degradation.
36. Pullmann R, Bonilla E, Phillips PE, et al. Haplotypes of the HRES-1 endogenous retrovirus are associated with development and disease manifestations of SLE. Arthritis Rheum 2008; 58:532-540. In this important review, a linkage disequilibrium between HRES-1 SNPs at bases 653 and 1259 was reduced in patients with SLE. The HRES-653C/1259C-harboring alleles were associated with the presence of renal disease, whereas the 956A allele was associated with the APS in APS patients with SLE. (Pubitemid 351294887)
37. Toubi E, Kessel A, Rosner I, et al. Quinacrine added to ongoing therapeutic regimens attenuates anticardiolipin antibody production in SLE. Lupus 2003; 12:297-301. (Pubitemid 36458660)